US FDA Explains How It Will Resume Inspections Suspended By Pandemic

Phased approach will prioritize the safety of FDA and industry employees while striking ‘an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.

3d different tablets and pills on a white background with question marks

The US Food and Drug Administration is developing a plan for resuming surveillance inspections suspended by the COVID-19 pandemic, according to a statement commissioner Stephen Hahn issued 11 May, three days after he self-quarantined due to possible exposure to the virus.

The plan, part of President Trump’s effort to reopen an economy devastated by fear of COVID-19, comes as routine testing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet